secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emergent BioSolutions Inc. (EBS)
CIK:        0001367644
Form:       8-K
Filed at:   2026-10-16T11:48:00+00:00
Accession:  0001367644-26-000098
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Emergent BioSolutions CFO Richard Lindahl to retire Dec 31, 2026; Frank Vargo named interim CFO
--------------------------------------------------------------------------------

- Richard S. Lindahl steps down as CFO and principal financial and accounting officer effective December 31, 2026, then serves as senior executive advisor through March 31, 2027 retirement.
- Frank Vargo, 43, VP and Treasurer since November 2025, becomes interim CFO and principal financial and accounting officer starting January 1, 2027.
- Vargo receives an additional $3,850 per pay period on top of his current $328,000 base salary, effective January 1, 2027; salary, bonus and equity remain commensurate with his prior seniority.
- Lindahl will assist with the transition, including preparation and filing of the Form 10-K for the year ending December 31, 2026; his advisor pay is materially consistent with current compensation.
- CEO Joe Papa thanked Lindahl for over eight years of service; the transition is tied to Emergent's multi-year transformation plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1367644/000136764426000098/0001367644-26-000098-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1367644/000136764426000098/ebs-20261016.htm
  HTML page:      https://secwatch.observer/filing/0001367644-26-000098

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer